ALS (motor neurone disease) trials in United States

In United States 91 Also abroad 226

91 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
Precise Robotically IMplanted Brain-Computer InterfacE
Where
Miami, Phoenix
Age
22 years to 75 years
People
15
Run by
Neuralink Corp
See details and how to joinNCT06429735
No phaseTaking people
Amyotrophic Lateral Sclerosis (ALS) Families Project
Where
New York
Age
18 years to 105 years
People
300
Run by
Columbia University
See details and how to joinNCT03865420
No phaseTaking people
Biospecimen Biorepository for the Study of ALS, ALS-FTD and Similar Neurodegenerative Disorders
Where
Jacksonville
Age
18 years and over
People
100
Run by
Mayo Clinic
See details and how to joinNCT05116943
No phaseTaking people
Imaging Biomarkers in ALS
Where
Minneapolis
Age
21 years to 75 years
People
30
Run by
University of Minnesota
See details and how to joinNCT02567136
No phaseTaking people
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)
Where
Sacramento
Age
18 years to 80 years
People
2
Run by
Leigh R. Hochberg, MD, PhD.
See details and how to joinNCT06094205
No phaseTaking people
Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures
Where
Boston, Chicago, Georgetown, Houston, Jacksonville, New York, Phoenix, San Diego, Seattle, St Louis
Age
18 years and over
People
1,000 worldwide
Run by
Target ALS Foundation, Inc.
See details and how to joinNCT05137665
No phaseNot yet taking people in United States
Resiliency Intervention for Patients With ALS and Their Care-Partners
Where
Boston
Age
18 years and over
People
20
Run by
Massachusetts General Hospital
See details and how to joinNCT06968468
No phaseNot yet taking people in United States
Augmented Reality BCI Longitudinal Study for Persons With ALS, Stroke, TBI and SCI Utilizing Cognixion + Apple Vision Pro
Where
Santa Barbara
Age
18 years and over
People
10
Run by
Cognixion
See details and how to joinNCT07209943
Phase 3Taking people
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
Where
Baltimore, Birmingham, Burlington, Charlottesville, Lexington, Los Angeles
Age
18 years to 81 years
People
495 worldwide
Run by
AB Science
See details and how to joinNCT03127267
Phase 1/2Not yet taking people in United States
A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS
Where
Boston
Age
18 years to 80 years
People
21 worldwide
Run by
SineuGene Therapeutics Co., Ltd.
See details and how to joinNCT07169175
No phaseEnrolling by invitation
Control of Assistive Devices Via Brain-Computer Interface Technology
Where
Phoenix
People
3
Run by
Neuralink Corp
See details and how to joinNCT06710626
Phase 3Not yet taking people in United States
Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)
Where
Aurora, Boston, Chicago, Davie, Jacksonville, La Jolla, Los Angeles, Philadelphia, Phoenix, Portland, Rochester, San Francisco, Tampa, Worcester
Age
18 years to 75 years
People
200
Run by
Brainstorm-Cell Therapeutics
See details and how to joinNCT06973629
Phase 1/2Taking people
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
Where
Jacksonville, San Francisco, Stanford
Age
18 years to 80 years
People
65
Run by
Ashvattha Therapeutics, Inc.
See details and how to joinNCT05395624
No phaseTaking people
ALS Research Collaborative
Where
Watertown
Age
18 years and over
People
2,000
Run by
ALS Therapy Development Institute
See details and how to joinNCT06885918
No phaseTaking people
NYSCF Scientific Discovery Biobank
Where
New York
Age
30 days and over
People
10,000
Run by
New York Stem Cell Foundation Research Institute
See details and how to joinNCT06203106
No phaseTaking people
Augmented Reality BCI Longitudinal Study for Persons With Late Stage ALS
Where
Santa Barbara
Age
18 years and over
People
10
Run by
Cognixion
See details and how to joinNCT06810219